Immunotherapy Clinical Trial Aims for Mesothelioma Cure

Medical oncologist Dr. Bernardo Goulart at the Seattle Cancer Care Alliance (SCCA) believes his latest clinical trial might be the most curative approach to treatment of pleural mesothelioma. He also believes it could work. Goulart is the principal investigator at SCCA, which has embraced a novel clinical trial that combines the immunotherapy drug Tecentriq (atezolizumab) with a multimodal regimen of chemotherapy, surgery and radiation. “The trial design is very intense, requiring multidisciplinary involvement,” Goulart told Asbestos.com. “I think it could provide insight into the next step of research that we will need to cure more people with this disease.” SCCA — which includes the Fred Hutchinson Cancer Research Center and the University of Washington Medical Center — is one of multiple sites conducting the clinical trial. The study is sponsored by the National Cancer Institute (NCI). Recruiting Patients to Participate Researchers are hoping for 28 surgical candidates to enroll nationwide. It will start with a chemotherapy and Tecentriq combination, then progress to aggressive surgery followed by possible radiation, and one year of Tecentriq follow-up maintenance. The study will require a substantial commitment from patients and medical center staff — more than the typical clinical trial. Those who undergo an extrapleural pneumonectomy (EPP) also will receive the high dose radiation. Patients having a pleurectomy and decorticat...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Erratum: P130cas is required for TGF-β1-mediated epithelial-mesenchymal transition in lung cancer. Oncol Lett. 2020 Apr;19(4):3358 Authors: Deng B, Tan QY, Wang RW, Jiang YG, Zhou JH, Huang W Abstract [This corrects the article DOI: 10.3892/ol.2014.2123.]. PMID: 32218871 [PubMed - as supplied by publisher]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Wang S, Meng C, Jiang Z, Gonzalez-Rivas D, Ruan J, Xu W, Liu C, Zhang L, Gao G, Yu G, Teng H, Ju J Abstract [This corrects the article DOI: 10.3892/ol.2019.10030.]. PMID: 32218870 [PubMed - as supplied by publisher]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Lu F, Cui D, Mu B, Zhao L, Mu P Abstract Tropomodulin-1 (TMOD1) is a key regulator of actin dynamics, which caps the pointed end of actin filaments. TMOD1 has been reported to be involved in several cellular processes, including neurite outgrowth, spine formation and cell migration. Increasing evidence demonstrates that TMOD1 is implicated in several aspects of cancer development. The present study aimed to investigate the role of TMOD1 in cervical cancer. HeLa and CaSki cell lines, derived from human cervical cancer, were used to evaluate the function of TMOD1. Cell motility was measured via a wound-heali...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Tian X, Wang N Abstract Pancreatic ductal adenocarcinoma (PDAC) remains a major cause of cancer-associated mortality, with poor patient outcome. The present study aimed to identify key candidate genes and investigate the potential molecular mechanisms associated with the progression of PDAC. The GSE46234 dataset was downloaded from the Gene Expression Omnibus database, in order to identify the upregulated differentially expressed genes (DEGs) in PDAC. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to determine the biological functions and pathways of the upreg...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Zhang Y, Bi L, Hu Z, Cao W, Zhuang D Abstract It has been found that>90% of oral cancer patients suffer from squamous cell carcinoma (SCC). The 5-year survival rate of SCC is ~50%, despite the availability of different treatments. Sonodynamic therapy (SDT) has been developed as a novel therapy for cancer, resisting bacterial infection and inhibiting atherosclerotic plaque progression. The present study investigated the efficacy of hematoporphyrin monomethyl ether (HMME)-mediated SDT on the A-253 epidermoid cancer cell line. The cytotoxicity of HMME and the survival rate of cells following SDT were exami...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Joe Abdo1, Christopher S. Wichman2, Nicholas E. Dietz1,3, Pawel Ciborowski4, John Fleegel1, Sumeet K. Mittal1,5 and Devendra K. Agrawal1* 1Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, United States 2Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States 3Department of Pathology, CHI Health Creighton University Medical Center, College of Medicine, Omaha, NE, United States 4Department of Pharmacology, University of Nebraska Medical Center, Omaha, NE, United States 5Norton Thoracic Institute, St....
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study supports the use of intravenous dexamethasone 10 mg before pemetrexed infusion in place of three days of oral dexamethasone 4 mg twice daily at UNMCCC,” the authors wrote. The post Alimta-Related Skin Reactions with and Without Oral Steroids appeared first on Mesothelioma Center - Vital Services for Cancer Patients &Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The FDA recently approved immunotherapy drug Tecentriq (atezolizumab) for certain bladder and non-small cell lung cancers, raising hopes for a mesothelioma-specific clinical trial in 2017. Tecentriq, a product of Genentech Oncology, is following the path of Keytruda (pembrolizumab) and Opdivo (nivolumab) as drugs that target a specific protein blocking a body’s immune system from attacking cancer cells. The U.S. Food and Drug Administration sanctioned Keytruda and Opdivo earlier for non-small cell lung cancer, and those drugs are working their way through the clinical trial process for the treatment of mesothelioma. ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: atezolizumab bladder cancer drug for mesothelioma immunotherapy for mesothelioma keytruda for mesothelioma opdivo for mesothelioma tecentriq Source Type: news
The immunotherapy drug avelumab showed promising results in a recent phase I clinical trial for malignant mesothelioma, raising hopes as a future second-line therapy. The clinical trial included 53 patients with pleural or peritoneal mesothelioma. It was part of the JAVELIN development program for avelumab, a series of clinical studies testing the drug on about 2,200 patients with more than 15 types of cancer. Merck and Pfizer are co-developing and marketing avelumab. Medical oncologist and mesothelioma specialist Dr. Raffit Hassan of the National Cancer Institute (NCI) presented the clinical trial results earlier this mon...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: clinical trial immunotherapy immunotherapy clinical trial immunotherapy for mesothelioma mesothelioma research mesothelioma treatment raffitt hassan Source Type: news
The U.S. Food and Drug Administration (FDA) recently granted approval for immunotherapy drugs Keytruda and Opdivo to fight non-small cell lung cancer, raising the hopes of patients with malignant pleural mesothelioma. Drugmakers Merck &Co. and Bristol-Myers Squibb manufacture Keytruda (pembrolizumab) and Opdivo (nivolumab), respectively. Both drugs target PD-1 and PD-L1, specific proteins that block a body's immune system from attacking the cancer cells. Those same proteins were identified in a subset of mesothelioma patients with the shortest survival times. The University of Chicago Comprehensive Cancer Center re...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news
More News: Asbestosis | Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Hospitals | Immunotherapy | Laparoscopy | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Study | University of Washington